Guardant Health Inc. (GH) shares surged 5.68% in pre-market trading on Friday, driven by a series of positive analyst actions.
JP Morgan raised its price target on Guardant Health to $135 from $130, while TD Cowen increased its target to $127 from $120. Barclays also lifted its target to $120 from $115. Additionally, William Blair reiterated its Buy rating on the stock.
These analyst upgrades reflect growing optimism about the healthcare company's prospects, contributing to the significant pre-market price movement.